Found 4 articles for: "Janus kinase inhibitors"
Immunosuppressive and Immunomodulatory Dermatologic Therapies: Cancer Risk for Patients With Active or Prior Malignancy
November 2026 | Volume 25 | Issue 11 | Original Article | 1045 | Copyright © November 2026
Background: The use of immunosuppressive and immunomodulatory medications in dermatology remains challenging in patients with active or prior malignancy due to concerns of cancer...
Read MoreProgression to Psoriatic Arthritis Among Psoriasis Patients Treated With JAK Inhibitors Compared With IL-17/23 Inhibitors
November 2026 | Volume 25 | Issue 11 | Original Article | 997 | Copyright © November 2026
Background: Psoriasis is a chronic immune-mediated inflammatory disease that may progress to psoriatic arthritis (PsA). Although multiple systemic therapies are available, includ...
Read MoreClinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study
August 2026 | Volume 25 | Issue 8 | Original Article | 732 | Copyright © August 2026
Background: Acne is a common cutaneous adverse event associated with Janus kinase (JAK) inhibitors, with incidence varying across agents. Substantial increase in JAK inhibitor us...
Read MoreEfficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
March 2026 | Volume 25 | Issue 3 | Original Article | 204 | Copyright © March 2026
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss on the scalp and body, leading to a reduced quality of life and psychosocial burden for patients. The only US ...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
